Pain Management in Sickle Cell Disease

Primary Analgesic Strategy

Opioids are the mainstay of acute pain treatment in sickle cell disease, with patient-controlled analgesia (PCA) showing superior outcomes compared to continuous infusion, including lower overall morphine consumption 1
Baseline long-acting opioid medications must be continued throughout the pain crisis if patients are already taking them for chronic pain management 2, 3

Sedation from diphenhydramine can mask critical warning signs such as early acute chest syndrome, which requires continuous oxygen saturation monitoring until SpO2 is maintained at baseline 3, 1
Anticholinergic effects may worsen dehydration, which is particularly dangerous since sickle cell patients have impaired urinary concentrating ability and dehydrate easily 2, 1
Sedation interferes with early mobilization, which is essential to prevent deep vein thrombosis—a significant risk in post-pubertal sickle cell patients 3, 1

Dopamine receptor antagonists (haloperidol, metoclopramide, prochlorperazine) are first-line for intractable vomiting 5
5-HT3 antagonists (ondansetron) should be added if vomiting persists despite dopamine antagonists 5

Initiate opioid therapy immediately using PCA when possible for moderate to severe pain 1
Maintain aggressive hydration with oral fluids preferred when possible, or IV fluids if oral intake is inadequate 2, 1
Monitor oxygen saturation continuously and administer oxygen to keep SpO2 above baseline or 96%, whichever is higher 3, 1

Do not assume opioid dependency in sickle cell patients—opioid dependency is actually rare in this population, while opioid sensitivity is more common 2
The American Society of Hematology recommends that opioid prescribing guidelines were not intended to deny clinically appropriate opioid therapy to individuals with sickle cell disease 4